BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Endometrial Cancer readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Endometrial Cancer\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04634877-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20261120
DTEND;VALUE=DATE:20261121
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT04634877)
DESCRIPTION:Pembrolizumab\, phase 3\, Endometrial Cancer.\nStudy: Study of 
 Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or 
 Without Radiotherapy in Participants With Newly Diagnosed Endometrial Canc
 er After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-e
 n11 / GOG-3053)\nEstimated primary completion: 20 November 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04634877
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03981796-2162@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20261126
DTEND;VALUE=DATE:20261127
SUMMARY:Dostarlimab: Phase 3 readout est. (NCT03981796)
DESCRIPTION:Dostarlimab\, phase 3\, Endometrial Cancer.\nStudy: A Study to 
 Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carbo
 platin-paclitaxel in Participants With Recurrent or Primary Advanced Endom
 etrial Cancer\nEstimated primary completion: 26 November 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT03981796
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04165772-2162@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT04165772)
DESCRIPTION:Dostarlimab\, phase 2\, Endometrial Cancer.\nStudy: Study of In
 duction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair De
 ficient Solid Tumors\nEstimated primary completion: 30 November 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dostarlimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04165772
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112991-994@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Envafolimab: Phase 2 readout est. (NCT05112991)
DESCRIPTION:Envafolimab\, phase 2\, Endometrial Cancer.\nStudy: Study of En
 vafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial C
 ancer\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05112991
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317311-2162@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT06317311)
DESCRIPTION:Dostarlimab\, phase 2\, Endometrial Cancer.\nStudy: A Study of 
 Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Partici
 pants With Primary Advanced or Recurrent Endometrial Cancer\nEstimated pri
 mary completion: 14 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/dostarlimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06317311
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585750-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04585750)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harborin
 g a TP53 Y220C Mutation (PYNNACLE)\nEstimated primary completion: 15 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4585750
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06253494-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06253494)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Endometrial Cancer.\nStudy: Pembrol
 izumab\, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 
 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants Wit
 h Advanced or Metastatic Endometrial Cancer\nEstimated primary completion:
  31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06253494
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05761951-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05761951)
DESCRIPTION:Pembrolizumab\, phase 2\, Endometrial Cancer.\nStudy: Phase 2 S
 tudy Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor\
 , Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Rec
 urrent Endometrial Cancer\nEstimated primary completion: 31 January 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05761951
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04774419-2162@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT04774419)
DESCRIPTION:Dostarlimab\, phase 2\, Endometrial Cancer.\nStudy: Radiation a
 nd TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Rece
 ive Surgery\nEstimated primary completion: February 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04774419
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05106127-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05106127)
DESCRIPTION:Pembrolizumab\, phase 2\, Endometrial Cancer.\nStudy: Safety Le
 ad-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem\
 nEstimated primary completion: March 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05106127
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05559879-2162@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Dostarlimab: Phase 1/2 readout est. (NCT05559879)
DESCRIPTION:Dostarlimab\, phase 1/2\, Endometrial Cancer.\nStudy: Cabozanti
 nib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma\nEstimated pri
 mary completion: April 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/dostarlimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05559879
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054567-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07054567)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: A Study of B
 L-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metas
 tatic Cervical Cancer and Endometrial Cancer\nEstimated primary completion
 : May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07054567
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02628067-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02628067)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: Study of Pem
 brolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-1
 58/KEYNOTE-158)\nEstimated primary completion: 4 May 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT02628067
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06366347-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06366347)
DESCRIPTION:Pembrolizumab\, phase 2\, Endometrial Cancer.\nStudy: ALPINE: M
 aintenance Letrozole/Abemaciclib\nEstimated primary completion: 1 Septembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063
 66347
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05123482-1986@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT05123482)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Phase I/IIa Study of AZD8205 Given Alone or Combined\, in Participants 
 With Advanced/Metastatic Solid Malignancies\nEstimated primary completion:
  29 September 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 ilvegostomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05123482
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05123482-2375@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Puxitatug samrotecan: Phase 1/2 readout est. (NCT05123482)
DESCRIPTION:Puxitatug samrotecan\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase I/IIa Study of AZD8205 Given Alone or Combined\, in Partic
 ipants With Advanced/Metastatic Solid Malignancies\nEstimated primary comp
 letion: 29 September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/puxitatug-samrotecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05123482
URL:https://assetmemo.bio/drug/puxitatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-1986@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT05489211)
DESCRIPTION:Rilvegostomig\, phase 2\, Biliary Tract Cancer.\nStudy: Study o
 f Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Pa
 tients With Advanced Solid Tumours (TROPION-PanTumor03)\nEstimated primary
  completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05489211
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07170982-2237@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 2 readout est. (NCT0717098
 2)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 2\, Endometrial Cance
 r.\nStudy: Fruquintinib Combined With Standard Chemotherapy Versus Standar
 d Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cance
 r\nEstimated primary completion: 15 October 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/fruquintinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07170982
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07044336-2375@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Puxitatug samrotecan: Phase 3 readout est. (NCT07044336)
DESCRIPTION:Puxitatug samrotecan\, phase 3\, Endometrial Cancer.\nStudy: Pu
 xitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected
  Endometrial Cancer (Bluestar-Endometrial01)\nEstimated primary completion
 : 15 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pu
 xitatug-samrotecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07044336
URL:https://assetmemo.bio/drug/puxitatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05077215-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05077215)
DESCRIPTION:Pembrolizumab\, phase 3\, Endometrial Cancer.\nStudy: Efficacy 
 and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem i
 n Advanced Endometrial Cancer\nEstimated primary completion: December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05077215
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06502743-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20271227
DTEND;VALUE=DATE:20271228
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06502743)
DESCRIPTION:Pembrolizumab\, phase 2\, Endometrial Cancer.\nStudy: First-lin
 e Carboplatin and Paclitaxel in Combination With Pembrolizumab\, Followed 
 by Maintenance Pembrolizumab With or Without Nesuparib\, in Patients With 
 Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Ca
 ncer\nEstimated primary completion: 27 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06502743
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06180733-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06180733)
DESCRIPTION:Pembrolizumab\, phase 2\, Endometrial Cancer.\nStudy: Neo-adjuv
 ant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer\nEst
 imated primary completion: 30 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06180733
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06132958-1991@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06132958)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Endometrial Cancer.\nStudy:
  Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy
  Endometrial Cancer (MK-2870-005)\nEstimated primary completion: 10 Januar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-t
 irumotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06132958
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867251-1992@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT05867251)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of AVZO-021 in Patients With Advanced Solid Tumors\
 nEstimated primary completion: 31 January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05867251
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06340568-2448@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Trastuzumab pamirtecan: Phase 3 readout est. (NCT06340568)
DESCRIPTION:Trastuzumab pamirtecan\, phase 3\, Endometrial Cancer.\nStudy: 
 A Clinical Study of the Anti-cancer Effects of an Investigational Therapy 
 or Chemotherapy in Patients With Recurring Uterine Cancer\nEstimated prima
 ry completion: March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/trastuzumab-pamirtecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06340568
URL:https://assetmemo.bio/drug/trastuzumab-pamirtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03682289-1959@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03682289)
DESCRIPTION:Durvalumab\, phase 2\, Urothelial Carcinoma.\nStudy: Ceralasert
 ib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patie
 nts With Solid Tumors\nEstimated primary completion: 31 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03682289
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07198074-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07198074)
DESCRIPTION:Pembrolizumab\, phase 3\, Endometrial Cancer.\nStudy: Testing t
 he Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carbo
 platin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMM
 R\, TP53 Mutated Endometrial Cancer\nEstimated primary completion: 1 July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07198
 074
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797168-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20280804
DTEND;VALUE=DATE:20280805
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05797168)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Pa
 rticipants With Solid Tumors\nEstimated primary completion: 4 August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05797168
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06463028-9074@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Serabelisib: Phase 2 readout est. (NCT06463028)
DESCRIPTION:Serabelisib\, phase 2\, Endometrial Cancer.\nStudy: Sapaniserti
 b and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-
 Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer\nE
 stimated primary completion: September 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/serabelisib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06463028
URL:https://assetmemo.bio/drug/serabelisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05086692-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05086692)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Beta-only IL-2 ImmunoTherapY Study\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05086692
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06746116-1959@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06746116)
DESCRIPTION:Durvalumab\, phase 3\, Endometrial Cancer.\nStudy: A Study to E
 valuate the Use of Durvalumab in Combination With Platinum-based Chemother
 apy Followed by Durvalumab With Olaparib as First-line Treatment in Advanc
 ed or Recurrent Endometrial Cancer in Spain\nEstimated primary completion:
  30 November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/du
 rvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06746116
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Rinatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Advanced Solid Tumo
 rs (GCT1184-01/ PRO1184-001)\nEstimated primary completion: December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-2708@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 1/2\, Non-Small Cell Lung
  Cancer.\nStudy: Rinatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Adv
 anced Solid Tumors (GCT1184-01/ PRO1184-001)\nEstimated primary completion
 : December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rina
 tabart-sesutecan-rina-s#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07832227-2266@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Selinexor: Phase 2 readout est. (NCT07832227)
DESCRIPTION:Selinexor\, phase 2\, Endometrial Cancer.\nStudy: Imlunestrant/
 Abemaciclib/Selinexor in Ovarian and Endometrial\nEstimated primary comple
 tion: 1 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/selinexor#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07832227
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06584032-2237@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0658403
 2)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3\, Endometrial Cance
 r.\nStudy: Study of Fruquintinib Plus Sintilimab for Treatment of Advanced
  Endometrial Cancer\nEstimated primary completion: 8 January 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06584032
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06989112-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20290119
DTEND;VALUE=DATE:20290120
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06989112)
DESCRIPTION:Pembrolizumab\, phase 3\, Endometrial Cancer.\nStudy: DESTINY-E
 ndometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostom
 ig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+)
 \, Mismatch Repair Proficient (pMMR) Endometrial Cancer\nEstimated primary
  completion: 19 January 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06989112
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06989112-1986@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20290119
DTEND;VALUE=DATE:20290120
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06989112)
DESCRIPTION:Rilvegostomig\, phase 3\, Endometrial Cancer.\nStudy: DESTINY-E
 ndometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostom
 ig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+)
 \, Mismatch Repair Proficient (pMMR) Endometrial Cancer\nEstimated primary
  completion: 19 January 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06989112
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07262619-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07262619)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: EIK1005-
 002: A Clinical Research Study Evaluating EIK1005\, a Werner Helicase Inhi
 bitor\, as Monotherapy and in Combination With Pembrolizumab in Participan
 ts With Advanced Solid Tumors Including Microsatellite Instability High (M
 SI-H) Tumors\nEstimated primary completion: March 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07262619
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07013851-2162@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT07013851)
DESCRIPTION:Dostarlimab\, phase 2\, Endometrial Cancer.\nStudy: Clinical Tr
 ial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patien
 ts With MMRd/MSI-H Stage II-III Endometrial Cancer\nEstimated primary comp
 letion: 1 March 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dostarlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07013851
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902999-2128@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20290423
DTEND;VALUE=DATE:20290424
SUMMARY:Sotiburafusp alfa: Phase 3 readout est. (NCT07902999)
DESCRIPTION:Sotiburafusp alfa\, phase 3\, Endometrial Cancer.\nStudy: HB002
 5-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as Firs
 t-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Canc
 er\nEstimated primary completion: 23 April 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/sotiburafusp-alfa#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07902999
URL:https://assetmemo.bio/drug/sotiburafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06486441-1992@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT06486441)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Endometrial Cancer.\nStudy: S
 tudy of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Pa
 rticipants With Endometrial Cancer After Platinum-Based Chemotherapy and I
 mmunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)\nEstimated primary comple
 tion: June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/saci
 tuzumab-govitecan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06486441
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07578649-1989@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:PF-08634404: Phase 3 readout est. (NCT07578649)
DESCRIPTION:PF-08634404\, phase 3\, Endometrial Cancer.\nStudy: Symbiotic-G
 YN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Com
 bination With Chemotherapy in Adult Participants With Advanced or Recurren
 t MMR-proficient Endometrial Cancer\nEstimated primary completion: 1 June 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pf-08634404#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0757864
 9
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684599-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20290723
DTEND;VALUE=DATE:20290724
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07684599)
DESCRIPTION:Pembrolizumab\, phase 3\, Endometrial Cancer.\nStudy: A Study t
 o Investigate Mocertatug Rezetecan as Maintenance Treatment for Participan
 ts With MMRp Endometrial Cancer (BEHOLD-Endometrial02)\nEstimated primary 
 completion: 23 July 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07684599
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684599-2162@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20290723
DTEND;VALUE=DATE:20290724
SUMMARY:Dostarlimab: Phase 3 readout est. (NCT07684599)
DESCRIPTION:Dostarlimab\, phase 3\, Endometrial Cancer.\nStudy: A Study to 
 Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants
  With MMRp Endometrial Cancer (BEHOLD-Endometrial02)\nEstimated primary co
 mpletion: 23 July 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/dostarlimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07684599
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07166094-2708@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 3 readout est. (NCT07166094)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 3\, Endometrial Cancer.\n
 Study: Study to Assess the Efficacy and Safety of Rina-S Compared to Treat
 ment of Investigator's Choice in Participants With Endometrial Cancer\nEst
 imated primary completion: August 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07166094
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05255653-1959@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Durvalumab: Phase 3 readout est. (NCT05255653)
DESCRIPTION:Durvalumab\, phase 3\, Endometrial Cancer.\nStudy: Refining Adj
 uvant Treatment IN Endometrial Cancer Based On Molecular Features\nEstimat
 ed primary completion: 1 January 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05255653
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07108270-2162@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT07108270)
DESCRIPTION:Dostarlimab\, phase 2\, Endometrial Cancer.\nStudy: A Study of 
 Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Particip
 ants With Primary Advanced or Recurrent Endometrial Cancer (EC)\nEstimated
  primary completion: 31 March 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07108270
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115927-2162@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT07115927)
DESCRIPTION:Dostarlimab\, phase 2\, Endometrial Cancer.\nStudy: pReOperativ
 e Dostarlimab and Novel Therapies in EndOmetrial Cancer\nEstimated primary
  completion: 30 April 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/dostarlimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07115927
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07860450-2162@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20301105
DTEND;VALUE=DATE:20301106
SUMMARY:Dostarlimab: Phase 3 readout est. (NCT07860450)
DESCRIPTION:Dostarlimab\, phase 3\, Endometrial Cancer.\nStudy: Two Part (P
 hase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclita
 xel in Participants With Primary Advanced or Recurrent Endometrial Cancer\
 nEstimated primary completion: 5 November 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07860450
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06040970-1992@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT06040970)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, Endometrial Cancer.\nStudy:
  Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive
  Recurrent Ovarian and Endometrial Cancer\nEstimated primary completion: 1
  July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzum
 ab-govitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06040970
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594015-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07594015)
DESCRIPTION:Pembrolizumab\, phase 2\, Endometrial Cancer.\nStudy: Pembroliz
 umab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Ca
 ncer After Progression on or Following First-Line Immunotherapy Maintenanc
 e\nEstimated primary completion: 31 August 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07594015
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952504-1973@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20320524
DTEND;VALUE=DATE:20320525
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06952504)
DESCRIPTION:Pembrolizumab\, phase 3\, Endometrial Cancer.\nStudy: A Study t
 o Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizu
 mab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With
  Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GO
 G-3119/ENGOT-en29)\nEstimated primary completion: 24 May 2032. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06952504
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952504-1991@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20320524
DTEND;VALUE=DATE:20320525
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06952504)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Endometrial Cancer.\nStudy:
  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With 
 Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Partici
 pants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroF
 use-033/GOG-3119/ENGOT-en29)\nEstimated primary completion: 24 May 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumoteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 952504
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06680739-1959@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20320701
DTEND;VALUE=DATE:20320702
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06680739)
DESCRIPTION:Durvalumab\, phase 2\, Endometrial Cancer.\nStudy: Single cEll 
 pRofiling PErsistaNce To ImmuNothErapy\nEstimated primary completion: 1 Ju
 ly 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06680
 739
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
